Total Payments
$106,805
2024 Payments
$28,645
Companies
12
Transactions
124
Medicare Patients
323
Medicare Billing
$124,067
Payment Breakdown by Category
Consulting$72,508 (67.9%)
Other$20,669 (19.4%)
Travel$10,277 (9.6%)
Food & Beverage$3,251 (3.0%)
Education$99.00 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $72,508 | 14 | 67.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $20,670 | 10 | 19.4% |
| Travel and Lodging | $10,277 | 44 | 9.6% |
| Food and Beverage | $3,251 | 55 | 3.0% |
| Education | $99.00 | 1 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Incyte Corporation | $74,889 | 85 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $25,534 | 24 | $0 (2024) |
| KADMON PHARMACEUTICALS LLC | $4,038 | 4 | $0 (2021) |
| CSL Behring | $1,000 | 1 | $0 (2020) |
| ZOLL Medical Corporation | $520.00 | 1 | $0 (2024) |
| National Marrow Donor Program | $214.51 | 1 | $0 (2024) |
| Eurofins Viracor, Inc. | $212.34 | 1 | $0 (2021) |
| JAZZ PHARMACEUTICALS INC. | $143.43 | 1 | $0 (2024) |
| Seres Therapeutics, Inc. | $119.92 | 2 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $72.60 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $28,645 | 41 | Incyte Corporation ($16,979) |
| 2023 | $41,612 | 40 | Incyte Corporation ($29,809) |
| 2022 | $31,236 | 35 | Incyte Corporation ($28,102) |
| 2021 | $240.18 | 2 | Eurofins Viracor, Inc. ($212.34) |
| 2020 | $4,955 | 3 | KADMON PHARMACEUTICALS LLC ($3,955) |
| 2019 | $55.52 | 1 | KADMON PHARMACEUTICALS LLC ($55.52) |
| 2018 | $30.00 | 1 | GENZYME CORPORATION ($30.00) |
| 2017 | $31.06 | 1 | Millennium Pharmaceuticals, Inc. ($31.06) |
All Payment Transactions
124 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/06/2024 | JAZZ PHARMACEUTICALS INC. | RYLAZE (Drug) | Food and Beverage | In-kind items and services | $143.43 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/01/2024 | Incyte Corporation | JAKAFI (Drug) | Consulting Fee | Cash or cash equivalent | $7,877.00 | General |
| Category: Hematology/Oncology | ||||||
| 10/30/2024 | SANOFI-AVENTIS U.S. LLC | REZUROCK (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,988.00 | General |
| Category: Oncology | ||||||
| 09/17/2024 | ZOLL Medical Corporation | Defibrillator (Device) | Consulting Fee | Cash or cash equivalent | $520.00 | General |
| Category: Resuscitation | ||||||
| 08/08/2024 | Incyte Corporation | — | Consulting Fee | Cash or cash equivalent | $6,165.00 | General |
| 08/08/2024 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $326.84 | General |
| 08/08/2024 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $284.95 | General |
| 08/08/2024 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $59.48 | General |
| 08/08/2024 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $56.94 | General |
| 08/08/2024 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $53.24 | General |
| 08/08/2024 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $29.87 | General |
| 08/08/2024 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $22.99 | General |
| 08/08/2024 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $22.59 | General |
| 08/08/2024 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $6.49 | General |
| 08/07/2024 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $219.00 | General |
| 08/07/2024 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $69.05 | General |
| 08/07/2024 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $41.37 | General |
| 08/07/2024 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $17.56 | General |
| 08/07/2024 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $7.07 | General |
| 08/07/2024 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $6.99 | General |
| 07/08/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $28.64 | General |
| Category: Hematology/Oncology | ||||||
| 05/06/2024 | SANOFI-AVENTIS U.S. LLC | REZUROCK (Drug) | Food and Beverage | In-kind items and services | $149.58 | General |
| Category: Oncology | ||||||
| 04/28/2024 | National Marrow Donor Program | — | Food and Beverage | In-kind items and services | $214.51 | General |
| 03/16/2024 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $36.30 | General |
| Category: ONCOLOGY | ||||||
| 03/16/2024 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $36.30 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 101 | 366 | $216,650 | $39,452 |
| 2022 | 2 | 74 | 181 | $115,610 | $19,636 |
| 2021 | 4 | 78 | 392 | $230,510 | $42,519 |
| 2020 | 4 | 70 | 240 | $129,250 | $22,461 |
Total Patients
323
Total Services
1,179
Medicare Billing
$124,067
Procedure Codes
13
All Medicare Procedures & Services
13 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 32 | 186 | $96,720 | $19,818 | 20.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 35 | 118 | $86,140 | $14,764 | 17.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 34 | 62 | $33,790 | $4,869 | 14.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 41 | 87 | $64,380 | $11,585 | 18.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 33 | 94 | $51,230 | $8,051 | 15.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 24 | 221 | $111,605 | $20,960 | 18.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 23 | 115 | $82,800 | $15,678 | 18.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 20 | 45 | $24,525 | $3,976 | 16.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 11 | 11 | $11,580 | $1,905 | 16.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 24 | 146 | $72,270 | $13,987 | 19.4% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 19 | 60 | $41,400 | $6,123 | 14.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 15 | 22 | $11,440 | $1,540 | 13.5% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2020 | 12 | 12 | $4,140 | $811.02 | 19.6% |
About Dr. Doris Ponce, MD
Dr. Doris Ponce, MD is a Hematology & Oncology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/29/2008. The National Provider Identifier (NPI) number assigned to this provider is 1114192242.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Doris Ponce, MD has received a total of $106,805 in payments from pharmaceutical and medical device companies, with $28,645 received in 2024. These payments were reported across 124 transactions from 12 companies. The most common payment nature is "Consulting Fee" ($72,508).
As a Medicare-enrolled provider, Ponce has provided services to 323 Medicare beneficiaries, totaling 1,179 services with total Medicare billing of $124,067. Data is available for 4 years (2020–2023), covering 13 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location New York, NY
- Active Since 04/29/2008
- Last Updated 01/17/2014
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1114192242
Products in Payments
- JAKAFI (Drug) $32,105
- REZUROCK (Drug) $21,596
- Defibrillator (Device) $520.00
- RYLAZE (Drug) $143.43
- VOWST (Drug) $119.92
- NINLARO (Drug) $103.66
- ELITEK (Drug) $30.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in New York
Jeffrey Zwicker, M.d, M.D
Hematology & Oncology — Payments: $1.2M
Hematology & Oncology $1.2M
Manuel Hidalgo Medina, M.d, M.D
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Dr. Ahmed Sawas, M.d, M.D
Hematology & Oncology — Payments: $807,524
Hematology & Oncology $807,524
Ruben Niesvizky, Md, MD
Hematology & Oncology — Payments: $734,512
Hematology & Oncology $734,512
Jeffrey Laurence, Md, MD
Hematology & Oncology — Payments: $706,018
Hematology & Oncology $706,018
Dr. Joshua Sabari, M.d, M.D
Hematology & Oncology — Payments: $603,205
Hematology & Oncology $603,205